1422253-38-0 manufacturers
- PRI-724
-
- $35.00
-
2026-08-30
- CAS:1422253-38-0
- Purity: 99.11%
- Supply Ability: 10g
|
| | 1422253-38-0 Basic information |
| Product Name: | 1422253-38-0 | | Synonyms: | 4-(((6S,9S,9aS)-1-(benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8- (quinolin-8-ylmethyl)octahydro-2H-pyrazino[2,1-c][1,2,4]triazin-6-yl) methyl)phenyl dihydrogen phosphate;4-(((6S,9S,9AS)-1-(BENZYLCARBAMOYL)-2,9-DIMETHYL-4,7-DIOXO-8- (QUINOLIN-8-YLMETHYL)OCTAHYDRO-2H-PYRA;2H-Pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide, hexahydro-2,9-dimethyl-4,7-dioxo-N-(phenylmethyl)-6-[[4-(phosphonooxy)phenyl]methyl]-8-(8-quinolinylmethyl)-, (6S,9S,9aS)-;4-(((6S,9S,9aS)-1-(benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(quinolin-8-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazin-6-yl)methyl)phenyl dihydrogen phosphate;4-[[(6S,9S,9aS)-1-(benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(quinolin-8-ylmethyl)-3,6,9,9a-tetrahydropyrazino[2,1-c][1,2,4]triazin-6-yl]methyl]phenyl] dihydrogen phosphate;FOSCENVIVINT (PRI-724);C-82 prodrug;ICG 001 analog | | CAS: | 1422253-38-0 | | MF: | C33H35N6O7P | | MW: | 658.64 | | EINECS: | | | Product Categories: | | | Mol File: | 1422253-38-0.mol |  |
| | 1422253-38-0 Chemical Properties |
| density | 1.48±0.1 g/cm3(Predicted) | | solubility | DMSO: Soluble: =10 mg/ml | | pka | 1.26±0.30(Predicted) | | form | Solid | | color | White to off-white | | InChIKey | VHOZWHQPEJGPCC-AZXNYEMZSA-N | | SMILES | N1(C)CC(=O)N2[C@@H](CC3=CC=C(OP(O)(O)=O)C=C3)C(=O)N(CC3=C4C(=CC=C3)C=CC=N4)[C@@H](C)[C@]2([H])N1C(NCC1=CC=CC=C1)=O |
| | 1422253-38-0 Usage And Synthesis |
| Uses | PRI 724 is a studied as a prospect for safely and effectively targeting catenin coactivator antagonism interactions to eliminate cancer stem cell population in human cancer. | | in vivo | PRI-724 is phosphorylated-C-82 and is rapidly hydrolyzed to its active form C-82 in vivo. PRI-724 treatment reduces the fibrosis induced by CCl4 or BDL. C-82, an active form of PRI-724, inhibits the activation of isolated primary mouse quiescent hepatic stellate cells (HSCs) and promotes cell death in culture-activated HSCs[1]. | | References | [1] Y. OSAWA. Inhibition of Cyclic Adenosine Monophosphate (cAMP)-response Element-binding Protein (CREB)-binding Protein (CBP)/β-Catenin Reduces Liver Fibrosis in Mice[J]. EBioMedicine, 2015, 58 1: 1751-1758. DOI: 10.1016/j.ebiom.2015.10.010
[2] ZEYUAN YU. A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination[J]. Oncogene, 2020, 40 5: 1027-1042. DOI: 10.1038/s41388-020-01572-w
[3] ROBERT KLESZCZ Jarosław P. The Wnt Signaling Pathway Inhibitors Improve the Therapeutic Activity of Glycolysis Modulators against Tongue Cancer Cells.[J]. International Journal of Molecular Sciences, 2022, 23 3. DOI: 10.3390/ijms23031248
[4] M MAVIGNER. Pharmacological Modulation of the Wnt/β-Catenin Pathway Inhibits Proliferation and Promotes Differentiation of Long-Lived Memory CD4+ T Cells in Antiretroviral Therapy-Suppressed Simian Immunodeficiency Virus-Infected Macaques.[J]. Journal of Virology, 2019, 94 1. DOI: 10.1128/jvi.01094-19 |
| | 1422253-38-0 Preparation Products And Raw materials |
|